Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases · 2026
DOI: 10.1016/j.ard.2025.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Lucia Santiago-Lamelas und 14 weiteren Autor:innen. Beteiligte Einrichtung: Immunogenetics Lab, Fundación Pública Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de investigación Sanitaria de Sa…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Transcriptome, Antirheumatic Agents, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: European Commission, Carlos III Health Institute, Ministerio de Economía y Competitividad.
Abstract (Originalsprache)
OBJECTIVES: This study aims to identify and validate a transcriptomic signature capable of predicting the response to tumour necrosis factor inhibitors (TNFi) therapy in patients with rheumatoid arthritis (RA) before treatment initiation. METHODS: We performed a retrospective transcriptomic analysis using 2 public datasets, RNA-seq data from peripheral blood mononuclear cells (GSE138746) and microarray data from whole blood (GSE33377), to define a small-scale gene signature predictive of the response to TNFi treatment. Three external validations were then conducted, resulting in a total of 279 individuals, 169 responders, and 110 nonresponders. RESULTS: Initial RNA-seq analysis (GSE138746) revealed 53 genes differentially expressed between responders and nonresponders; however, none of these genes remained significant after P value adjustment with the Benjamini-Hochberg method. A small-scale genetic signature comprising the 18 most discriminatory genes was then developed, achieving a leave-one-out cross-validation predictive accuracy of 88.75%. We further refined this list to 7 genes (COMTD1, MRPL24, DNTTIP1, GLS2, GTPBP2, IL18R1, and KCNK17) that effectively predicted the response to TNFi treatment, with an area under the receiver operating characteristic curve (AUC) of 0.84 in the GSE33377 dataset. Internal validation of the GSE138746 dataset yielded an AUC = 0.89. Finally, external validation confirmed the robustness of the 7-gene model (AUC ≥ 0.85). CONCLUSIONS: We identified a transcriptomic signature that aids the prediction of the response to TNFi treatment in patients with RA. These findings support its potential use as a precision medicine tool to improve therapeutic decision-making and reduce exposure to ineffective treatments in patients with RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunogenetics Lab, Fundación Pública Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.
- Immunogenetics Lab, Fundación Pública Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain; Faculty of Health…
- Group of Inverse Problems, Optimization and Machine Learning, Department of Mathematics, University of Oviedo, Oviedo, Spain; Department of Computer Science, University of Oviedo, Oviedo, Spain.
- Group of Inverse Problems, Optimization and Machine Learning, Department of Mathematics, University of Oviedo, Oviedo, Spain; DeepBioInsights, Oviedo, Spain.
- Rheumatology Service, Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
- Department of Inflammation and Immunology, Pfizer, Cambridge, MA, USA.
Förderung
- European Commission
- Carlos III Health Institute
- Ministerio de Economía y Competitividad
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Galicia Health Service
- Junta de Andalucía
Zitieren
APA
Santiago-Lamelas, L., Castro-Santos, P., deAndrés-Galiana, E. J., Fernández-Martínez, J. L., Escudero-Contreras, A., Pérez-Sanchez, C., Sánchez-Pareja, I., López-Pedrera, C., Jelinsky, S. A., Nikitsina, M., Gonzalez-Alvaro, I., Sobrín, R. D. S., Mera, A., Durán, J., & Díaz-Peña, R. (2026). Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.08.003
Vancouver
Santiago-Lamelas L, Castro-Santos P, deAndrés-Galiana EJ, Fernández-Martínez JL, Escudero-Contreras A, Pérez-Sanchez C, et al. Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.08.003
BibTeX
@article{SantiagoLamelas2026,
author = {Santiago-Lamelas, Lucia and Castro-Santos, Patricia and deAndrés-Galiana, Enrique J and Fernández-Martínez, Juan Luis and Escudero-Contreras, Alejandro and Pérez-Sanchez, Carlos and Sánchez-Pareja, Ismael and López-Pedrera, Chary and Jelinsky, Scott A and Nikitsina, Maryia and Gonzalez-Alvaro, Isidoro and Sobrín, Raquel Dos Santos and Mera, Antonio and Durán, Josefina and Díaz-Peña, Roberto},
title = {Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
doi = {10.1016/j.ard.2025.08.003}
}
EUVIMED